An observational study in Mitral Valve Insufficiency and Coronary Artery Disease, sponsored by Icahn School of Medicine at Mount Sinai. Active, not recruiting at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Icahn School of Medicine at Mount Sinai · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Mitral Valve Insufficiency with a site in United States — 33 open to participants now, 53 under way, none of them phase 3. Mitral Valve Insufficiency · United States.
Among the 118 studies in Mitral Valve Insufficiency with a site in United States, this one is the 14th largest by enrollment of the 37 observational ones that give a count, is one of 10 that started in 2017, is one of 37 observational ones, reaches primary completion later than 28 of the 52 other live ones, and was the 48th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →33 of the 118 studies in Mitral Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Capstan Medical · Sites in United States
Ages 18+
Abbott Medical Devices · Sites in United States
Ages 18+
Polares Medical SA · Sites in United States
Ages 21+
InnovHeart · Sites in United States
Ages 18+
Nyra Medical, Inc. · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4 · Phase 4 4
First in 1992; this study’s year is marked. 10 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 368 is above the median of 159 across 170 observational studies indexed under Mitral Valve Insufficiency.
Median enrollment 60 across the 81 interventional studies, 200 across the 37 observational. Of the 52 that completed or were terminated, 26 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 118 have an industry lead sponsor. The 10 most frequent:
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
Icahn School of Medicine at Mount Sinai has 3 studies filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
13 of the studies in Mitral Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04408430Mayra GuerreroThe MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves). | 2026-12 |
| NCT07655505Intuitive SurgicalUse of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair | 2026-12-31 |
| NCT05061004Abbott Medical DevicesCephea Early Feasibility Study | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT06738615Atlantic Health SystemAssessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity | 2027-01-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 118 studies in Mitral Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a continuation of two previous studies --- the Severe Ischemic Mitral Regurgitation (SMR) Trial (NCT00807040) and the Moderate Ischemic Mitral regurgitation (MMR) Trial (NCT00806988) --- to learn more about patients' health 5-10 years after their mitral valve surgeries. The investigators will collect long-term health information on SMR and MMR trial participants using electronic medical records, patient and/or family input, public records, and healthcare- and vital status-related databases.
This study is a continuation of two CTSN randomized trials --- the Severe Ischemic Mitral Regurgitation (SMR) Trial (NCT00807040) and the Moderate Ischemic Mitral regurgitation (MMR) Trial (NCT00806988) --- for the purpose of assessing the long-term outcomes of the index surgical therapies. Key clinical outcomes will be collected utilizing electronic medical records, patient and/or family input, public records, and healthcare- and vital status-related databases. Extended follow-up data will be obtained on up to 199 SMR and 270 MMR trial participants, who were alive at their 2-year follow-up evaluation. Patients will be followed for a minimum of 5 years and up to 10 years after randomization (the time of index surgical procedure). This follow-up data collection will be conducted by the Cardiothoracic Surgical Trials Network (CTSN) primarily utilizing the minimal PHI necessary to link data obtained from the MMR and SMR trials to other healthcare- and/or vital status-related databases.
Because the design of surgical trials for ischemic mitral regurgitation that would use mortality as a primary endpoint requires the enrollment of thousands of patients, the selected primary endpoint for the CTSN SMR and MMR trials was an echocardiographic measure of left ventricular remodeling. Secondary endpoints included, among others, survival, adverse events, readmissions and costs over a 2-year period. The SMR trial showed no difference in left ventricular reverse remodeling, but the rate of moderate or severe mitral regurgitation recurrence was significantly higher with mitral valve repair, resulting in more heart failure-related adverse events and cardiovascular admissions. Longer-term follow-up will be critical to assess whether this observed trend amongst SMR patients will continue and whether a survival difference will manifest over time. In moderate ischemic mitral regurgitation, mitral valve repair provided a more durable correction of mitral regurgitation than coronary artery bypass grafting (CABG) alone, but repair did not improve survival or reduce overall adverse events or readmissions, and was associated with an early hazard of neurological and supraventricular arrhythmic events. Longer-term follow-up of MMR patients will provide insights into whether the higher degree of recurrent mitral regurgitation with CABG alone will be associated with differences in adverse events, readmissions and survival. Additionally, the benefits of alternative surgical treatments for ischemic mitral regurgitation, which have differential upfront risks and costs, will likely extend beyond 2 years. Cost-effectiveness analysis will delineate the long-term cost-benefit trade-offs between mitral valve repair versus replacement for SMR, and of CABG with repair versus CABG alone for MMR, which should inform surgical decision making, and examine how differences in life expectancy and risk profiles of different patient groups affect cost-effectiveness over time. This extended follow-up should provide important clinical and health policy insights.
Randomized patients in the MMR and SMR trials who were still alive at 2 years after the index cardiac surgical intervention
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.
Other: MV Repair
This group of patients had been randomized in the SMR study to mitral valve replacement.
Other: MV Replacement
This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.
Other: MV Repair
This group of patients had been randomized in the MMR study to receive CABG
Other: CABG
Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
Also known as: Mitral Valve Repair
Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
Also known as: Mitral Valve Replacement
Participants underwent coronary artery bypass grafting
Also known as: Coronary Artery Bypass Grafting
Survival
All-cause mortality will be assessed.
Time frame: up to 10 years post-surgery (at the time of registry data transfer)
Repeat Cardiac Interventions for MR
Repeat cardiac interventions for MR in particular will be determined for the duration of follow-up and will be analyzed using a time-to-event analysis.
Time frame: up to 10 years post-surgery (at the time of registry data transfer)
Hospital Costs
Hospital costs will be calculated for the duration of follow-up utilizing the minimum PHI necessary to link the CTSN databases to other databases (e.g., Vizient, CMS Medicare, and Canadian Province databases). Cost data will be extracted from the Vizient operational database system for member sites or national payer or state-wide databases. Dates of charges and revenue codes will be used to match the cost data with data on readmissions. We will estimate costs including center-specific ratios of cost to charges. These ratios will be based on the annual Medicare costs reports submitted annually by participating study sites to Medicare. These data will be used to impute data for patients treated at hospitals, which are non-Vizient members.
Time frame: up to 10 years post-surgery (at the time of registry data transfer)
Cost Effectiveness
Cost Effectiveness using Incremental Cost Effectiveness Ratio and Net Health Benefit parameters. The primary objective of the cost-effectiveness analysis (CEA) is to estimate the incremental cost-effectiveness ratio (ICER) of the intervention under investigation as compared to the study-defined alternative. This ratio measures the ratio of the difference in costs and outcomes between the two study arms for each trial, with outcomes measured as life-years. We will also compute net health benefits (NHB) as an alternative way of looking at cost-effectiveness. This parameter compares the incremental effectiveness of an intervention with the minimum health effect that society would demand in return for the investment; i.e., with the health produced by investing at the societal ceiling cost-effectiveness ratio.
Time frame: up to 10 years post-surgery (at the time of registry data transfer)
Plan to share: No
No publications or documents are linked to this record.
Started May 2017 (actual). Primary completion is estimated for Jul 2027, 122 months after the start.
Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 122 months is above that.
Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →